TAIPEI (CNA) – John Mendelsohn, one of three winners of the 2018 Tang Prize for biopharmaceutical science, died at his Houston home in the United States late Monday night. He was 82, according to the Tang Prize Foundation.
Mendelsohn, president emeritus of Texas University’s MD Anderson Cancer Center, succumbed to a glioblastoma, the most aggressive form of brain cancer, after being diagnosed with the disease 15 months ago.
Alongside Tony Hunter and Brian Druker, Mendelsohn received the Tang Prize last year for his research into protein tyrosine phosphorylation and tyrosine kinase as oncogenes, which has led to successful targeted cancer therapies.
Mendelsohn and his team conducted pre-clinical research and developed the anti-epidermal growth factor receptor (EGFR) antibody cetuximab (Erbitux®), which eventually received approval from the U.S. Food and Drug Administration for the treatment of colon cancer and head/neck cancer, the foundation said.
The MD Anderson Cancer Center became the No.1 cancer hospital in the U.S. under the leadership of Mendelsohn, who served as its president from 1996-2011.
By Chen Chih-chung and Flor Wang